A Cost Analysis of Somatostatin use in the Prevention of Pancreatic Fistula after Pancreatectomy

[1]  C. Moulton,et al.  Comparison of outcomes and costs between laparoscopic distal pancreatectomy and open resection at a single center , 2012, Surgical Endoscopy.

[2]  N. Machado.  Pancreatic fistula after pancreatectomy: definitions, risk factors, preventive measures, and management-review. , 2012, International journal of surgical oncology.

[3]  M. Shabahang,et al.  Novel Method of Stump Closure for Distal Pancreatectomy with a 75% Reduction in Pancreatic Fistula Rate , 2012, Journal of Gastrointestinal Surgery.

[4]  J. Moalem,et al.  The Influence of Staple Size on Fistula Formation Following Distal Pancreatectomy , 2012, Journal of Gastrointestinal Surgery.

[5]  J. Galloway,et al.  Risk Factors for Pancreatic Fistula after Stapled Gland Transection , 2011, The American surgeon.

[6]  K. Gurusamy,et al.  Meta-analysis of randomized controlled trials on the effectiveness of somatostatin analogues for pancreatic surgery: a Cochrane review. , 2010, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[7]  W. Lau,et al.  Measures to prevent pancreatic fistula after pancreatoduodenectomy: a comprehensive review. , 2009, Archives of surgery.

[8]  S. Shrikhande,et al.  Pancreatic fistula after pancreatectomy: evolving definitions, preventive strategies and modern management. , 2008, World journal of gastroenterology.

[9]  D. Mortimer,et al.  Review of Australian health economic evaluation – 245 interventions: what can we say about cost effectiveness? , 2008, Cost effectiveness and resource allocation : C/E.

[10]  S. Shrikhande,et al.  Pancreatic resectional surgery: an evidence-based perspective. , 2008, Journal of cancer research and therapeutics.

[11]  A. Jawas,et al.  Use of octreotide for the prevention of pancreatic fistula after elective pancreatic surgery: a systematic review and meta-analysis. , 2007, Canadian journal of surgery. Journal canadien de chirurgie.

[12]  J. Cameron,et al.  One Thousand Consecutive Pancreaticoduodenectomies , 2006, Annals of surgery.

[13]  P. Pattyn,et al.  Prospectively Randomized Trial Using Perioperative Low-dose Octreotide to Prevent Organ-related and General Complications after Pancreatic Surgery and Pancreatico-jejunostomy , 2005, World Journal of Surgery.

[14]  S. Connor,et al.  Meta‐analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery , 2005, The British journal of surgery.

[15]  J. Neoptolemos,et al.  Postoperative pancreatic fistula: an international study group (ISGPF) definition. , 2005, Surgery.

[16]  J. Neoptolemos,et al.  Current standards of surgery for pancreatic cancer , 2004, The British journal of surgery.

[17]  A. J. Donovan,et al.  Pancreaticoduodenectomy: A 20-year experience in 516 patients , 2004 .

[18]  H. Friess,et al.  Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma , 2004, The British journal of surgery.

[19]  S. Msika,et al.  Octreotide in the prevention of intra-abdominal complications following elective pancreatic resection: a prospective, multicenter randomized controlled trial. , 2004, Archives of surgery.

[20]  Y. Shan,et al.  Role of Somatostatin in the Prevention of Pancreatic Stump-related Morbidity following Elective Pancreaticoduodenectomy in High-risk Patients and Elimination of Surgeon-related Factors: Prospective, Randomized, Controlled Trial , 2003, World Journal of Surgery.

[21]  M. Sarr.  The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial. , 2003, Journal of the American College of Surgeons.

[22]  B. Gayet,et al.  Randomized controlled multicentre trial of somatostatin infusion after pancreaticoduodenectomy , 2001, The British journal of surgery.

[23]  D. Rattner,et al.  Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. , 2001, Archives of surgery.

[24]  K. Campbell,et al.  Does Prophylactic Octreotide Decrease the Rates of Pancreatic Fistula and Other Complications After Pancreaticoduodenectomy?: Results of a Prospective Randomized Placebo-Controlled Trial , 2000, Annals of surgery.

[25]  D. Winchester,et al.  Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. , 1999, Journal of the American College of Surgeons.

[26]  M. Haas,et al.  The Economic Evaluation of Health Care , 1998, Health information management : journal of the Health Information Management Association of Australia.

[27]  Jeffrey E. Lee,et al.  Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. , 1997, Annals of surgery.

[28]  R Robinson,et al.  Economic evaluation and health care. What does it mean? , 1993, BMJ.

[29]  R. Meier,et al.  Pharmacodynamic effects of Sandostatin in the gastrointestinal tract. , 1992, Metabolism: clinical and experimental.

[30]  C. Beglinger,et al.  Effect of a New Somatostatin Analogue on Pancreatic Function in Healthy Volunteers , 1986, Pancreas.

[31]  P. Marbach,et al.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. , 1982, Life sciences.

[32]  I. Klempa,et al.  [Prevention of postoperative pancreatic complications following duodenopancreatectomy using somatostatin]. , 1979, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[33]  J. Mezhir.  Management of complications following pancreatic resection: An evidence‐based approach , 2013, Journal of surgical oncology.

[34]  F. Mosca,et al.  Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial. , 1995, Surgery.

[35]  R. Meier,et al.  Pharmacodynamic effects of Sandostatin in the gastrointestinal tract. , 1993, Digestion.

[36]  G. Weisz.  Prevention and management of pancreatic fistula. , 1971, Review of surgery.